The last several decades have witnessed considerable progress in our understanding of the pathogenesis, refining diagnostic criteria, and identifying therapies of value for modifying the course of relapsing forms of multiple sclerosis. While the pace of progress has lagged for those with progressive phase disease, this now seems to be changing. This review considers those characteristics of patients with primary progressive multiple sclerosis that may contribute to phase 3 trial success and identifies some of the thorny issues that remain ahead. The larger of the studies conducted thus far have sequentially informed our understanding of "pure" primary progressive disease, and also challenge both phase 3 and especially phase 2 trial designs and participant selection for investigations going forward. This may have particular relevance for testing therapeutics directed at neuroprotection and repair in the face of ongoing progression regardless of trial participant categorization using current conventional disease phenotypes.
Introduction
Precise disease definitions are critical to unravel the pathogenesis of any condition, ultimately facilitating developing effective disease-modifying therapies (DMTs). Early in the process, one is confronted with understanding whether the varied nature of clinical presentations reflect fundamental differences in pathogenesis, or complexity of disease evolution across affected individuals. Defining diagnostic criteria for a given disease as well as any variations in its clinical presentation that might specify phenotypes of major pathogenic significance is an iterative process; one which even with modern tools can be a rather inexact science. Approaches to better delineate both diagnostic criteria and definitions of phenotypic variation for describing multiple sclerosis (MS) have accelerated over the last several decades, arguably propelled in part by early therapeutic successes in managing critical elements of disease pathogenesis. 1 Central to current diagnostic and clinical phenotype definitions have been lessons learned from single and multicenter natural history studies, clinical trials, and incorporation of relevant disease biomarkers. As a consequence, the field has progressed from definitions that were primarily expert consensus opinion, 2, 3 to ones considerably more evidence-based. 4, 5 We have generally moved to classification of patients as having relapsing multiple sclerosis (RMS) with or without accumulating disability but stability between clinical relapses, to those with progressive disease from onset in the absence of attacks, or who transitioned to a clinically progressive phase with fewer ongoing attacks. In all phases, subclinical new lesion activity found on magnetic resonance imaging (MRI) further defines the disease state at a given epoch of time. We now recognize that individuals with MS can be identified in the absence of clinical symptoms or findings required for diagnosis, but with imaging abnormalities on MRI consistent with the disease (RIS-radiologically isolated syndrome), 6 who over time may pass into definite RMS or primary progressive multiple sclerosis (PPMS). 7 The failure, thus far, to clearly separate any of the clinical phenotypes based on conclusive genetic, immunological, imaging, or pathologic features leaves some to think of the disease as reflecting a spectrum as characterized in Figure 1 . What does this mean in constructing new trials for progressive disease, and how did trials in PPMS evolve to their current state?
Patient selection and trial design in PPMS
The early success in controlled clinical trials of patients with RMS raised the issue if patients with progressive forms of the disease would also respond to these therapies. This initially stimulated studies in secondary progressive multiple sclerosis (SPMS), excluding patients with PPMS. Nonetheless, several studies were launched that specifically addressed patients with clinical courses fundamentally the same as or quite similar to what we now consider as PPMS. 8 An earlier study that reported patients with "chronic progressive" MS included a subcohort of patients with clear progression from onset without relapses, or at most a single relapse that had occurred 10 or more years prior to onset of progression without subsequent relapses before their consideration for trial entry. 9 That subcohort was used to model sample size for a large phase 3 clinical trial of glatiramer acetate in patients with more rigorously defined PPMS. 10 While that "PROMiSe trial" was finalized, diagnostic criteria for MS in general and PPMS specifically were under debate. Of particular concern was whether the presence of intrathecal synthesis of immunoglobulins as documented by the laboratory-based finding of cerebrospinal fluid (CSF)-specific oligoclonal immunoglobulin (IgG) bands, or elevated IgG index, or IgG synthesis rate was an essential diagnostic feature of PPMS. 3, 11, 12 At nearly the same time, a single-center trial was initiated in Barcelona that included both patients with PPMS and "transitional" progressive MS. 13 The baseline clinical characteristics of the largest of the controlled, phase 3 clinical trials in PPMS completed thus far are displayed in Table 1 . [14] [15] [16] [17] Notably different characteristics of patients recruited into these trials include the time from onset of first symptoms (shortest in the fingolimod and ocrelizumab trials), age at trial entry (youngest in the ocrelizumab study), and proportion of subjects with enhancing lesions on entry MRI (lower in the glatiramer acetate and fingolimod trials). The differences reflect decisions on trial entry criteria based on data gleaned over the course of these sequential studies.
PROMiSe trial patient screening commenced in July 1999 using entry criteria that were similar to those later adopted by the international panel, 3 with the exception that positive CSF was not mandatory. The study candidate's CSF IgG status was required before entry based on source document review as positive at some time in the past, or negative if done within the year prior to entry. When unknown, or previously deemed negative, CSF evaluation was performed and reviewed, but these results did not preclude eligibility. Ultimately, 21.6% of those randomized were CSF negative.
This planned 3-year trial of active therapy was stopped early based on a futility analysis, but patients were RIS: radiologically isolated syndrome; CIS: clinically isolated syndrome; MS: multiple sclerosis. Horizontal arrows represent directional conversions (transitions) from one phase or phenotype of multiple sclerosis to another. Note that one phase does not necessarily ever pass to another and that the first clinical episode can be CIS or the onset of relapsing multiple sclerosis depending on subclinical MRI findings at the time of presentation. Note also that the arrow representing conversion from RIS to PPMS has no passage through CIS, RMS, or SPMS.
invited to be followed off study drug until the originally projected study termination date. Several important observations emerged. Males randomized to placebo appeared to progress more rapidly than did their female counterparts, where progression onset was demarcated as a defined increase in Expanded Disability Status Scale (EDSS) confirmed 3 months later (confirmed disability progression, CDP). The effect of active treatment on curtailment of on-study new lesion development appeared similar to that expected for the drug as seen for RMS. CSF-positive subjects progressed more rapidly (hazard ratio (HR) = 1.38) than those who were CSF negative. 18 The presence of one or more gadolinium-enhanced lesions on the entry scan was associated with an increased proportion of subjects who progressed over the first 24 months on trial; 42.1% compared to 30.8% for those without baseline enhancements. Additionally, the CSFpositive cohort was more likely to have a baseline enhancement than those who were CSF negative.
The trial of rituximab in PPMS subjects (OLYMPUS) drew from some of PROMiSe study experiences including sample size projections. Participant enrollment began in June 2004, adhering to the original international panel criterion that patients be shown CSF positive within 2 years or at screening for entry. 15 Although the study failed to meet its primary objective of reduction in the time to 12-week CDP in the absence of relapse, preplanned subgroup analyses suggested that patients entering the trial under 50 years of age and with one or more enhancements on their cerebral MRI had a much reduced chance on trial progression (HR = 0.33, confidence interval (CI) = 0.14-0.79, p = 0.0088). 15 Exploration of the data suggested that subjects with better entry EDSS scores of 3.0-<5.0 and disease duration <10 years from onset had more favorable benefits from active therapy. Subsequent modeling of the trial's database supported the use of composite endpoints to include patients evidencing a 12-week 20% sustained change from baseline for the timed 25-foot walk test (T25FWT), or 9-hole peg test (9HPT), or CDP based on EDSS as a full set, or paired sets compared to the standard CDP by EDSS alone; comparisons were also done for more stringent 24-week CDP. 19 Others have explored the power of these endpoints as well; 20 but to date, these composite outcomes have not been explored by baseline patient characteristics that might improve the outcome sensitivity by study enrichment.
The trial of 1.25 mg fingolimod compared to placebo in PPMS subjects (INFORMS) was initiated in September 2008. A subsequent decision that a lower 0.5 mg dose used in relapsing-remitting multiple sclerosis (RRMS) trials should be submitted to regulatory authorities dictated recruiting a second active cohort at the 0.5 mg dose randomized to placebo in November 2009. 16 The 2005 revisions of McDonalds criteria 12 were used with stipulations that reported first symptoms had occurred within a 2-to 10-year window, with documented progression in the last 2 years of defined magnitude and entry T25FWT of <30 seconds. The study used the composite endpoint of 12-week CDP by EDSS, or 20% confirmed change from baseline by T25FWT, or 9HPT as the primary outcome. There was no discernible evidence of drug effect on these clinical endpoints, but the expected effects on relapses and new brain activity measures were seen. There was no significant reduction in brain volume loss observed as seen in the RRMS trials with fingolimod. 21 Nonetheless, among the small subgroup of patients with two or more gadolinium-enhancing lesions at baseline, those randomized to placebo had accelerated brain volume loss compared to those on fingolimod.
A larger proportion of participants randomized to placebo showed 12-week CDP using the composite (Kaplan-Meier estimate = 80.3%) than any of its three components (T25FWT = 70.0%, EDSS = 58.7%, 9HPT = 41.3%). 16 While the numbers of patients remaining at risk for CDP fell rapidly after 3 years on trial (by prior progression, early discontinuation, or end of study), the majority of subjects to experience a first CDP had done so within 3 years, suggesting that longer trials of PPMS could not provide any further informative data using these sensitive composite endpoints to delineate worsening.
The randomized, controlled trial of ocrelizumab in PPMS (ORATORIO) began patient enrollment in March 2011. Entry criteria and other aspects of the study design were influenced by the OLYMPUS trial. Diagnosis rested on the 2005 McDonald criteria, 12 with the exception that documented evidence of intrathecal IgG synthesis was required. As a strategy to enroll participants earlier in their clinical course, symptom onset under 15 years was required for those with a screening EDSS > 5.0 and under 10 years for those with an EDSS ≤5.0, with a 55-year upper age enrollment limit. Those with any prior clinical relapses were excluded. Recruited patients were younger, with shorter clinical courses than those in the OLYMPUS trial with a similar proportion of participants having one or more enhancements on their entry brain MRI (see Table 1 ). Sample size calculations projected 253 progression events were required to meet assumptions of rates of worsening, proportions of participant dropouts, and treatment effect size for the primary outcome of 12-week CDP based on EDSS. The trial's duration was dictated by attaining this number of events. A predefined hierarchical approach to statistical analysis of the primary and all secondary endpoints was used. The primary endpoint was met (HR = 0.76, CI = 0.58-0.98, p = 0.04) and supported by the first secondary outcome of 24-week CDP. 17 While hierarchical testing broke at the fifth secondary level, most other secondary and exploratory analyses supported the superiority of active treatment on other clinical and MRI disease markers. Subgroup analyses of primary, secondary, and exploratory analyses of the effect of baseline gadolinium enhancement status on these outcomes were not adequately powered for definitive inferences, but trends (not all internally consistent) suggested better outcomes for those with MRI-based subclinical activity at trial entry (see Table S5 Appendix material from Montalban, et al 2017 17 ).
Implications and concerns for future PPMS trial designs
The frequency of clinically evident relapses; the addition of MRI-monitoring and the rapid delineation of the frequency of new brain lesion formation/activity based on gadolinium-enhancing lesions, new and enlarging T2-weighted hyperintense lesions, and combined unique lesion activity across the MS clinical phenotypes; and the effects of first-generation DMTs facilitated refinement of trial designs for phase 2 and phase 3 studies in RMS. The infrequency of these markers of acute lesional activity in PPMS has complicated efficient phase 3 trial design and rendered more conventional phase 2 designs using RRMS outcomes as inappropriate for PPMS.
What might be lessons of the larger PPMS trials that could be used in future patient selection? Males generally appear to worsen more rapidly than their female counterparts. However, using gender as a selection criteria would greatly impede recruitment and generality of results. Nonetheless, sensitivity analyses of outcomes should include gender, and perhaps trial duration might be extended were gender differences appear to be introducing biased accumulation of onstudy event rates. As positive CSF status appears to associate with the likelihood of new lesion activity and rates of worsening, this likely should be a trial eligibility requirement. While the presence of intrathecal IgG synthesis currently is not a requirement for the diagnosis of MS, absence of this feature should raise concerns very early in the course of the disease, especially for those with PPMS. This criterion, when used for research/clinical trials, need not imply a lack of generality of results. Using the presence of new lesion activity at entry into trials would greatly complicate PPMS trial recruitment, and would be rendered moot should PPMS trials move to requiring patients be on best available "anti-inflammatory" DMTs, when testing therapies designed to limit neurodegeneration or to facilitate repair. What can and probably should be used for enrichment is to focus on recruitment of patients in the earliest clinical phases of PPMS using age, duration of disease based on first symptoms, or time from diagnosis.
While eligibility requirements to meet some definition of pre-entry "trajectory" of disease worsening is attractive, this implies pre-entry documentation that may impede trial recruitment and force enrollment toward an older trial cohort. Moreover, recent rates of deterioration might not assure maintenance of the tempo of worsening of a participant once enrolled and could by default move further from, rather than closer to, gathering subjects in the earliest clinical phases of PPMS. Additionally, if the proportion of MS patients presenting with the PPMS phenotype is indeed falling, as suggested by an analysis of the Swedish MS registry, 22 then each added restrictive trial entry criterion might only compound timely trial recruitment from a possibly waning clinical phenotype.
There is little evidence that clinical progression, independent of clinical or MRI-defined subclinical inflammatory activity, differs between those with SPMS or PPMS once established. 5, 23 As suggested by many, careful design of trials for progressive phase MS could enable more rapid study enrollment. However, reliable early delineation of SPMS onset remains problematic despite quite thoughtful modeling attempts. 24 This might complicate finding benefits of newer anti-inflammatory DMTs on confirmed progression in mixed SPMS/PPMS trials if started with variable delay in characterizing progressive phase onset. Stratification of randomization and preplanned subgroup analyses would need special attention. Alternatively, if the objective were impacting progression in study populations whose relapse and MRI-defined subclinical inflammatory was optimally controlled with anti-inflammatory DMTs, this might provide the most accessible population for evaluating the promise of agents targeting neurodegeneration or repair. The caution here is not for the design of the phase 3 study of these novel or repurposed neuroprotective/repair therapies in a progressive population, but how to reduce the risk of undertaking such trials.
While we have proven approaches for phase 2 studies in RMS with high success rates when moved to phase 3, the path to phase 3 trials in progressive phase MS is far less clear. One approach might be "proof of concept" trials where the putative mechanism of action (MOA) proposed for the drug must be confirmed in early phase 2 in the appropriate MS phenotype patient before embarking to definitive phase 3 studies. This could be a two-step process of first showing that the agent has no effect on the systemic immune system that could be immunomodulatory.
The second is more difficult and needs be tailored to the putative MOA. As an example, if the drug is anticipated to stabilize mitochondrial injury or improve energy stores, then one might require evidence that regional energy metabolism is improved as implied by better N-acetyl aspartate levels on spectroscopic imaging. Should remyelination be central to the proposed MOA, then the immediate goal might be demonstration that magnetization transfer ratios, diffusion tensor imaging metrics, or myelin water content of some lesions is favorably changed over the short term to warrant embarking on clinically measurable and meaningful changes in the longer term.
